Immuno-Oncology Diagnostics Markets

SEE the Table of Contents.

GET the Free Sample of this Report.

Many organizations subscribe to all or some of our reports.  You may already have free access to this report. FIND out Here.

"Market Forecasts for Immuno-Oncology Diagnostics. Including Executive/Consultant Guides and Customized Forecasting/Analysis.  2023 to 2027"

450 Pages packed with information 

Explosion in immuno-oncology therapies creates an exploding diagnostic market. Diagnostics plays new key role in Therapeutic Development and Clinical Trials….

Diagnostics, companion diagnostics, is driving the success of Immuno-oncology Therapeutics.  An entire new segment of the diagnostics industry is being created.  And its not a small segment either.  It promises to grow dramatically.  Histology, genomics and liquid biopsy are converging.  A complicated network of pharmaceutical companies, diagnostic companies and instrumentation suppliers are jockeying for position in a new approach to conquering cancer.  The approach seems to be working and showing great promise.

 A revolution in cancer therapy is underway.  New therapy based on using the body’s natural immune defenses is having unprecedented success.  But diagnostics, especially biomarkers are desperately needed to help select the right therapy.

 The technology is moving faster than the market.  The impact on the health care industry is enormous.  Tumor Mutational Burden?  Checkpoint Inhibitors?  Cytokines?  Find out about the technology in readily understood terms that explain the jargon.  Find the opportunities and the pitfalls.  Understand growth expectations and the ultimate potential market size in this new expanded and comprehensive report.

SEE the Table of Contents.

GET the Free Sample of this Report.

Many organizations subscribe to all or some of our reports.  You may already have free access to this report. FIND out Here.

ABOUT THE LEAD AUTHOR

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research.  His education includes:

Finance for Senior Executives - Harvard Business School

Market Research  - Burke Institute

M.B.A. (Finance and Policy) - University of British Columbia

B.Sc. (Chemistry) - University of British Columbia

He is an experienced business and clinical professional.  He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping."  He has worked in laboratory testing and management for over 20 years.